Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease

Lignende værker

• Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
  af: Chen, Shuchun, et al.
  Udgivet: (2018)
• Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
  af: Bader, Miaad, et al.
  Udgivet: (2018)
• PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease
  af: Yu, Seong-Jin, et al.
  Udgivet: (2020)
• Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration
  af: Kim, Jeongah, et al.
  Udgivet: (2018)
• Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats
  af: Eakin, Katharine, et al.
  Udgivet: (2013)